{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:10:57Z","timestamp":1787890257561,"version":"build-2784847793"},"reference-count":35,"publisher":"BMJ","issue":"e3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,2,8]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the cost-effectiveness of addition of olanzapine to a prophylactic antiemetic regimen containing aprepitant, dexamethasone and ondansetron among children receiving highly emetogenic chemotherapy (HEC) in India, Bangladesh, Indonesia, the UK and the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Health states were estimated using individual patient-level outcome data from a randomised trial. The incremental cost\u2013utility ratio (ICUR), incremental cost-effectiveness ratio and net monetary benefit (NMB) were calculated from the patient perspective for India, Bangladesh, Indonesia, the UK and the USA. One-way sensitivity analysis was done by varying the cost of olanzapine, cost of hospitalisation and utility values by \u00b125%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The olanzapine arm had an increment of 0.0018 quality-adjusted life-years (QALY) over the control arm. The mean total expenditure in the olanzapine arm was greater by US$0.51, US$0.43, US$6.73, US$11.05 and US$12.35 in India, Bangladesh, Indonesia, the UK and the USA, respectively. The ICUR($\/QALY) was US$282.60 in India, US$241.42 in Bangladesh, US$3755.93 in Indonesia, US$6161.83 in the UK and US$6887.41 in the USA. The NMB was US$9.86, US$10.12, US$14.08, US$44.74 and US$98.79 for India, Bangladesh, Indonesia, the UK and the USA, respectively. The ICUR estimates of the base case and sensitivity analysis were below the willingness-to-pay threshold in all scenarios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The addition of olanzapine as a fourth agent for antiemetic prophylaxis is cost-effective despite an increase in overall expenditure. Olanzapine should be uniformly considered for children receiving HEC.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2022-004069","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T18:20:20Z","timestamp":1677090020000},"page":"e1272-e1279","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents"],"prefix":"10.1136","volume":"13","author":[{"given":"Manraj Singh","family":"Sra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramavath Devendra","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak Kumar","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azgar","family":"Abdul Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"2024051713152755000_13.e3.e1272.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21631"},{"key":"2024051713152755000_13.e3.e1272.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2714-9"},{"key":"2024051713152755000_13.e3.e1272.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002595"},{"key":"2024051713152755000_13.e3.e1272.4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.2017.35.31_suppl.155","article-title":"Hospitalization costs for nausea and vomiting: a savings opportunity","volume":"35","author":"Roeland","year":"2017","journal-title":"JCO"},{"key":"2024051713152755000_13.e3.e1272.5","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1016\/S1470-2045(21)00468-X","article-title":"Financial toxicity in cancer care in india: a systematic review","volume":"22","author":"Boby","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024051713152755000_13.e3.e1272.6","doi-asserted-by":"crossref","unstructured":"Mardakis S , Arora RS , Bakhshi S , et al . A qualitative study of the costs experienced by caregivers of children being treated for cancer in new delhi, india. Cancer Reports 2019;2. doi:10.1002\/cnr2.1149","DOI":"10.1002\/cnr2.1149"},{"key":"2024051713152755000_13.e3.e1272.7","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.20.00871","article-title":"Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial","volume":"38","author":"Naik","year":"2020","journal-title":"JCO"},{"key":"2024051713152755000_13.e3.e1272.8","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28532","article-title":"Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: an open-label, randomized phase 3 trial","volume":"67","author":"Radhakrishnan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2024051713152755000_13.e3.e1272.9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MPH.0000000000002408","article-title":"Efficacy and safety of olanzapine in children receiving highly emetogenic chemotherapy: a randomized, double-blind placebo-controlled phase 3 trial","volume":"44","author":"Moothedath","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2024051713152755000_13.e3.e1272.10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0041-1737011","article-title":"Antiemetic regimen with olanzapine in pediatric patients receiving highly emetogenic chemotherapy","volume":"42","author":"Rasheed","year":"2021","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2024051713152755000_13.e3.e1272.11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study","volume":"27","author":"Chanthawong","year":"2019","journal-title":"Support Care Cancer"},{"key":"2024051713152755000_13.e3.e1272.12","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1007\/s00520-020-05977-x","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"key":"2024051713152755000_13.e3.e1272.13","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29795","article-title":"Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: individual patient data analysis of a randomized trial","volume":"69","author":"Sra","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2024051713152755000_13.e3.e1272.14","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462313000160"},{"key":"2024051713152755000_13.e3.e1272.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5"},{"key":"2024051713152755000_13.e3.e1272.16","unstructured":"Online pharmacy india | buy medicines from india\u2019s trusted medicine store: 1mg.com. 1mg. Available: https:\/\/www.1mg.com\/ [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.17","unstructured":"IndiaMART . IndiaMART - indian manufacturers suppliers exporters directory,india exporter manufacturer. Available: https:\/\/www.indiamart.com [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.18","unstructured":"Arogga.com. home - arogga - online pharmacy of bangladesh. Available: https:\/\/www.arogga.com\/ [Accessed 23 May 2022]."},{"key":"2024051713152755000_13.e3.e1272.19","unstructured":"APCOM . Best online surgical equipment | medical disposable product. n.d. Available: https:\/\/apcombd.com"},{"key":"2024051713152755000_13.e3.e1272.20","unstructured":"Bed list charges | evercare hospital dhaka. Available: https:\/\/www.evercarebd.com\/bed-list-charges\/ [Accessed 23 May 2022]."},{"key":"2024051713152755000_13.e3.e1272.21","unstructured":"RS kanker dharmais | pusat kanker nasional | dharmais cancer center hospital. Available: https:\/\/dharmais.co.id\/ [Accessed 23 May 2022]."},{"key":"2024051713152755000_13.e3.e1272.22","unstructured":"k24klik . PT k24klik indonesia K. about k24klik.com. Available: https:\/\/www.k24klik.com\/tentang-k24klik [Accessed 23 May 2022]."},{"key":"2024051713152755000_13.e3.e1272.23","unstructured":"NICE . BNF. Available: https:\/\/www.nice.org.uk\/bnf-uk-only [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.24","unstructured":"NHS England . National tariff payment system documents, annexes and supporting documents. Available: https:\/\/www.england.nhs.uk\/publication\/national-tariff-payment-system-documents-annexes-and-supporting-documents\/ [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.25","unstructured":"GOV.UK . NHS reference costs. Available: https:\/\/www.gov.uk\/government\/collections\/nhs-reference-costs [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.26","unstructured":"Logistics O of P Acquisition and, Pharmaceutical Prices . Office of procurement, acquisition and logistics (OPAL). Available: https:\/\/www.va.gov\/opal\/nac\/fss\/pharmPrices.asp [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.27","unstructured":"Drugs.com . Prescription drug information, interactions & side effects. Available: https:\/\/www.drugs.com\/ [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.28","unstructured":"Medical supply store - USA medical & surgical supplies. Available: https:\/\/www.usamedicalsurgical.com\/ [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.29","unstructured":"Price information. Available: https:\/\/www.nationwidechildrens.org\/your-visit\/billing-and-insurance\/pay-my-bill\/price-information-list [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.30","unstructured":"Healthcare cost and utilization project (HCUP). Available: https:\/\/www.ahrq.gov\/data\/hcup\/index.html [Accessed 10 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.31","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0672-z"},{"key":"2024051713152755000_13.e3.e1272.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0710-6"},{"key":"2024051713152755000_13.e3.e1272.33","unstructured":"Baltussen R , Adam T , et al . Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization; 2003. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/42699 [Accessed 15 Feb 2022]."},{"key":"2024051713152755000_13.e3.e1272.34","unstructured":"Data . GDP per capita (current US$). Available: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD [Accessed 23 May 2022]."},{"key":"2024051713152755000_13.e3.e1272.35","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1481"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-004069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:51:44Z","timestamp":1715986304000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-004069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":35,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2022-004069"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-004069","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]}}}